Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma

NCT03913923 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma
Melanoma Metastatic

Interventions

BIOLOGICAL: BCD-217
BIOLOGICAL: BCD-100
OTHER: Placebo

Sponsor

Biocad